Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis
Sign Up to like & getrecommendations! Published in 2019 at "Neuromuscular Disorders"
DOI: 10.1016/j.nmd.2019.06.002
Abstract: Rituximab is a chimeric monoclonal antibody that binds CD20 and causes the depletion of B-cell subsets. Although initially designed to treat lymphoma, it has found wide use in the management of various autoimmune conditions, including… read more here.
Keywords: agents initiation; stopping oral; steroid sparing; oral steroid ... See more keywords